99mTc-ixolaris targets glioblastoma-associated tissue factor: In vitro and pre-clinical applications

Barboza, Thiago; Gomes, Tainá; Mizurini, Daniella M.; Monteiro, Robson Q.; König, Sandra; Francischetti, Ivo M.B.; Signoretti, Paula V.P.; Ramos, Isalira Peroba; Gutfilen, Bianca; Souza, Sérgio Augusto Lopes de

doi:10.1016/j.thromres.2015.05.032

Cited by 10 publications

(9 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The second technique used was Sephadex G-75 gel filtration chromatography (n = 3), which separates the compounds by molecular weight. In this experiment it was demonstrated that the complex formed 99m Tc-Ixolaris was blunt, and its elution was detected early when compared to Na 99m TcO4, this data has been published in Barboza et al, 2015. The third and final technique for determination of radiochemical purity was thin layer chromatography using silica gel coated fiber sheets (TLC-SG) (n = 6) (table 2), using acetone and 85% methanol as the solvent for determination of the amount of TcO4and TcO 2 , respectively.…”

Section: Radiopharmaceuticalsupporting

confidence: 51%

Preclinical dosimetric evaluation of Ixolaris labeled with 99mTc and Translacional Model

Figueiredo¹,

Lopes

Barboza³

et al. 2019

Braz. J. Rad. Sci.

Self Cite

View full text Add to dashboard Cite

This study aimed to determine the biokinetic model for Ixolaris labelled with 99mTc radiotracer in mice by means of an imaging dosimetry method to estimate the absorbed and effective doses resulting from the diagnosis of melanoma and metastases in humans. C57BL6 mice induced animals with cell line B16-F10 murine melanoma were tested. It was determined by Single Photon Emission Tomography Computed (SPECT) images a latency period of 15 to 21 days for the development of lung metastasis in mice. The 99mTc-Ixolaris radiopharmaceutical was intravenously administered in a caudal vein, and SPECT images were acquired approximately at 0.5 h, 1.5 h, 2.5 h, 3.5 h and 24 h post-administration for analysis and biodistribution quantification. The biokinetic model was determined and cumulative activity to estimate the absorbed dose in each organ was calculated. The mass and metabolic differences between mice and humans were considered and used to extrapolate the data for different scales. Absorbed doses in irradiated target organs were calculated for the source organs based on dose factors provided by the software MIRDOSE and Olinda/EXM (S factor). Afterwards, the effective doses were estimated. The metabolic differences were 7,02 in this study. The dosimetric results indicated an estimated effective dose of 4.3 mSv for diagnostic exams conducted in human melanoma patients for an administered activity of 25.7 MBq. Comparing with effective doses resulting from other 99mTc diagnostic techniques, effective dose ranging from 0.6 to 4.8 mSv it was concluded that the procedure should proceed into a Clinical Phase in humans.

show abstract

Section: Radiopharmaceuticalsupporting

confidence: 51%

Preclinical dosimetric evaluation of Ixolaris labeled with 99mTc and Translacional Model

Figueiredo¹,

Lopes

Barboza³

et al. 2019

Braz. J. Rad. Sci.

Self Cite

View full text Add to dashboard Cite

show abstract

“…It decreases tumor vascularization and VEGF expression and reduces tumor growth in vitro and in vivo [164][165][166]. In addition, Ixolaris is also being tested in a 99m Tc-conjugated form for radiological tumor diagnosis [167]. The complex and dynamic interplay of these and many other factors orchestrates the phases of wound healing including functional differentiation of macrophages, interaction of immigrating cells with endothelial cells, fibroblasts, and keratinocytes, as well as cell differentiation and restoration of tissue integrity.…”

Section: Another Anti-angiogenic Salivary Component With Oncological ...mentioning

confidence: 99%

The tick and I: Parasite‐host interactions between ticks and humans

Schön

2022

J Deutsche Derma Gesell

View full text Add to dashboard Cite

Summary Ticks, particularly hard ticks (Ixodidae), which are among the most important vectors of dangerous infectious agents, feed on their hosts for extended periods of time. With this lifestyle, numerous adaptations have evolved in ticks and their hosts, the pharmacological importance of which is increasingly being recognized. Many bioactive substances in tick saliva are being considered as the basis of new drugs. For example, components of tick cement can be developed into tissue adhesives or wound closures. Analgesic and antipruritic salivary components inhibit histamine or bradykinin, while other tick‐derived molecules bind opioid or cannabinoid receptors. Tick saliva inhibits the extrinsic, intrinsic, or common pathway of blood coagulation with implications for the treatment of thromboembolic diseases. It contains vasodilating substances and affects wound healing. The broad spectrum of immunomodulatory and immunosuppressive effects of tick saliva, such as inhibition of chemokines or cellular immune responses, allows development of drugs against inflammation in autoimmune diseases and/or infections. Finally, modern vaccines against ticks can curb the spread of serious infections. The medical importance of the complex tick‐host interactions is increasingly being recognized and translated into first clinical applications. Using selected examples, an overview of the mutual adaptations of ticks and hosts is given here, focusing on their significance to medical advance.

show abstract

“…Indeed, a Kunitz-domain protein Ir-CPI ( Ixodes ricinus contact phase inhibitor) was shown to be a very efficient inhibitor of the contact phase of the coagulation cascade (Decrem et al, 2009), which is now being exploited in pre-clinical testing 1 . As well as hemostasis regulation, the Kunitz inhibitors Ixolaris and Amblyommin-X have displayed anti-cancer therapeutic potential (Carneiro-Lobo et al, 2009; Chudzinski-Tavassi et al, 2010; Barboza et al, 2015; de Souza et al, 2016).…”

Section: Tick Salivary Protein Families With Therapeutic Potentialmentioning

confidence: 99%

The Use of Tick Salivary Proteins as Novel Therapeutics

et al. 2019

View full text Add to dashboard Cite

The last three decades of research into tick salivary components have revealed several proteins with important pharmacological and immunological activities. Two primary interests have driven research into tick salivary secretions: the search for suitable pathogen transmission blocking or "anti-tick" vaccine candidates and the search for novel therapeutics derived from tick salivary components. Intensive basic research in the field of tick salivary gland transcriptomics and proteomics has identified several major protein families that play important roles in tick feeding and overcoming vertebrate antitick responses. Moreover, these families contain members with unrealized therapeutic potential. Here we review the major tick salivary protein families exploitable in medical applications such as immunomodulation, inhibition of hemostasis and inflammation. Moreover, we discuss the potential, opportunities, and challenges in searching for novel tick-derived drugs.

show abstract

99mTc-ixolaris targets glioblastoma-associated tissue factor: In vitro and pre-clinical applications

Cited by 10 publications

References 49 publications

Preclinical dosimetric evaluation of Ixolaris labeled with 99mTc and Translacional Model

Preclinical dosimetric evaluation of Ixolaris labeled with 99mTc and Translacional Model

The tick and I: Parasite‐host interactions between ticks and humans

The Use of Tick Salivary Proteins as Novel Therapeutics

Contact Info

Product

Resources

About